Computational finding of potential inhibitor for Cytochrome P450 Mono-oxygenases Enzyme of <i>Mycobacterium tuberculosis</i>

BACK TO CONTENTS | PDF | PREVIOUS | NEXT

Title	Computational finding of potential inhibitor for Cytochrome P450 Mono-oxygenases Enzyme of Mycobacterium tuberculosis
Authors	Ashwani Sharma¹*, Krishna K Subbias^2$, Ophélie Robine^3$, Indu Chaturvedi^4$, Anshul Nigam^{1, 5$}, Nishant Sharma⁶, Prem Prashant Chaudhary^7$
Affiliation	¹Center of drug discovery research, New Era Proteomics, C-1/31, Yamuna Vihar, New Delhi-110053, India; ²Department of Chemical Engineering, Indian Institute of Technology Bombay, Mumbai – 400076, India; ³Mass Spectrometry center, New Era Proteomics, 83 route de Grimard, 33670 Créon, France; ⁴Department of Animal Nutrition, Central Institute of Research on Goats (C.I.R.G.), Makhdoom, Farah, Mathura, UP-281122, India; ⁵Interdisciplinary Programme in Life Science, Pondicherry University,Puducherry-605014 India; ⁶Institute of Human Behaviour & Allied Sciences (IHBAS), Jhilmil, Dilshad Garden Delhi-110095, India; ⁷Biowits Life Sciences, Computational Biology Section, Yamuna Nagar-135001 ,Haryana, India
Email	ashwansharma@gmail.com; *Corresponding author
Article Type	Hypothesis
Date	Received September 15, 2012; Accepted September 19, 2012; Published October 01, 2012
Abstract	Cytochrome P450 mono-oxygenases (2UUQ) enzyme from Mycobacterium tuberculosis catalyzes oxidation of organic compounds such as lipids and steroidal hormones therefore remain as potential drug target. Currently available first line anti-tuberculosis drugs have been caused several side effects in the body as well as resistance development by mycobacterium against these drugs, necessitates the considerable need for finding new drugs. Therefore, we propose a structure based computational method to find a new potential inhibitor for cytochrome P450 mono-oxygenases enzyme. Compounds from several ligand databases were docked against the functional sites of 2UUQ (A) through the standard GEMDOCK v2.0 and AUTODOCK4.0 molecular docking tools. Commercially available chemical compound ZINC00004165 (5-[3-(2-nitroimidazol-1-yl) propyl] phenanthridine) has produced top rank with lowest interaction energy of -113.2 (via GEMDOCK) and lowest docking energy of -9.80 kcal/mol (via AUTODOCK) as compared to first line anti TB compounds. Z score and normal distribution analysis verified that the ZINC00004165 compound has more affinity towards 2UUQ in comparison to large number of random population of compounds. ZINC00004165 is also in agreement with the drug likeness properties of Lipinski rule of five without any violation. Therefore, our finding concludes that the commercial compound ZINC00004165 can act as a potential inhibitor against cytochrome P450 mono-oxygenases enzyme of Mycobacterium tuberculosis.
Keywords	Cytochrome P450 mono-oxygenases, Tuberculosis, Ligand database, Docking, Gemdock, Autodock
Citation	*Sharma et al.* Bioinformation 8(19): 931-937 (2012)
Edited by	P Kangueane
ISSN	0973-2063
Publisher	Biomedical Informatics
License	This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.